Barbara Kittner

Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report

Priya S. Kishnani, David Kronn, Anaïs Brassier et al. · Genetics in Medicine · 2022 · 52 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

Clinical Trial Designs for Demonstrating Disease-Course-Altering Effects in Dementia

Peter J. Whitehouse, Barbara Kittner, Martin Roessner et al. · Alzheimer Disease & Associated Disorders · 1998 · 47 citations

Medicine, Neuroscience, Pharmacology +15

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Gili Kenet, Beatrice Nolan, Bülent Zülfikar et al. · Blood · 2024 · 41 citations · Full text

Medicine, Hematology, Pharmacology +15

Preliminary Results from an MRI/CT‐Based Database for Vascular Dementia and Alzheimer's Disease

Philip Scheltens, Barbara Kittner · Annals of the New York Academy of Sciences · 2000 · 33 citations · Full text

Medicine, Neurology, Neuroscience +16

Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis

Frank C. Hampel, Barbara Kittner, Julius H. van Bavel · Annals of Allergy Asthma & Immunology · 2007 · 29 citations

Pharmacy, Pediatrics, Pharmacotherapy +14